ADVM
Adverum Biotechnologies Inc
Adverum Biotechnologies Inc
$ADVM Reports Strong Progress in Phase 2 LUNA Trial for Wet AMD in Q1 2023 Financial Results
Adverum Biotechnologies has revealed progress in their Phase 2 LUNA trial for wet AMD, with enrollment set to complete in H2 2023 and preliminary safety and efficacy data expected in Q4 2023. The company's gene therapy product candidate, Ixo-vec, has shown promise in phase 1 trials, with sustained efficacy through three years. Adverum is the only ocular gene therapy company in wet AMD with Fast Track Designation from the FDA, and has gained regulatory designations from the European Medicines Agency and UK's MHRA. While the financial position looks stable, investors should be aware of potential risks and uncertainties related to clinical trials and regulatory approvals.
4mo ago
$ADVM